Compare Duolingo Inc (DUOL) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Duolingo Inc trades at $150.02 (market cap $7.08B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B). The key difference: Duolingo Inc is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DUOL | IOVA | |
|---|---|---|
Market Cap | $7.08B | $6.04B |
Volume | 729,171 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $341.08 | $14.82 |
52-Week Low | $90.03 | $1.81 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $5.85B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $149.92, down 1.19% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $0.66 versus $0.60, continuing a pattern of earnings outperformance. Revenue growth remains robust at 39% year-over-year for 2025, reaching $1.04 billion, while maintaining exceptional profitability with a 35.87% net income margin. Technical indicators show a bullish moving average configuration despite neutral oscillators.
Duolingo presents a compelling growth story with accelerating revenue expansion and industry-leading margins, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share sales totaling $4.3 million in September 2026 and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, suggesting the stock may be fairly valued near current levels despite strong operational performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
